Jun 04, 2020
INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea
May 20, 2020
INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models
May 14, 2020
INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
May 12, 2020
INOVIO to Present at RBC Capital Markets Virtual Global Healthcare Conference
May 11, 2020
INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
May 05, 2020
May 2020 Deadline Approaching for Inovio Pharmaceuticals (INO) Class Action
Apr 30, 2020
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
Apr 28, 2020
INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
Apr 28, 2020
INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference
Apr 15, 2020
INOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time
Apr 12, 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Apr 06, 2020
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
Mar 30, 2020
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
Mar 24, 2020
Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant
Mar 18, 2020
INO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Alerts Inovio Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Mar 13, 2020
INO Stock: Berger Montague Investigates Securities Fraud Class Action Claims Against Inovio Pharmaceuticals, Inc. (NASDAQ: INO); Lead Plaintiff Deadline is May 12, 2020
Mar 12, 2020
INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results
Mar 02, 2020
Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Mar 02, 2020
Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Feb 10, 2020
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)